A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors

Solid Tumors Clinical Trial

Official title:

A Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics of a Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Patients With Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02705963
• Other study ID #: CTMT212X2102
• Status: Completed
• Phase: Phase 1
• Start date: October 20, 2016
• Est. completion date: August 29, 2019

Study information

• Verified date: October 2021
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effect of trametinib once daily on the pharmacokinetics (PK) of a daily dosing oral contraceptives (OCs) containing norethindrone (NE) and ethinyl estradiol (EE) in female patients with solid tumors. The PK of trametinib and its metabolite M5 will also be assessed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: August 29, 2019
• Est. primary completion date: August 29, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 59 Years

Eligibility

Inclusion Criteria:

• Has a histologically or cytologically confirmed diagnosis of a solid tumor malignancy (except for any excluded malignancies listed in the Exclusion Criteria) that is not responsive to standard therapy(ies) or for which there is no approved therapy.
• Meets one of the following criteria: Is currently on a stable regimen of an oral contraceptive containing 1mg NE and 0.035mg EE, or Is willing to switch to a regimen of an oral contraceptive containing 1mg NE and 0.035mg EE from a stable regimen of an alternate OC, or Is willing to start a regimen of an oral contraceptive containing 1mg NE and 0.035mg EE.
• Meets one of the following criteria: Is post-menopausal, or, Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, must use highly effective methods of contraception during dosing and for four months after stopping medication.
• Has no prior treatment-related toxicities >Grade 1 (except alopecia) at the time of enrolment.
• Patient must meet the following laboratory values at the screening visit: Absolute Neutrophil Count =1.5 x 109/L. Platelets =75 x 109/L. Hemoglobin (Hgb) =9 g/dL. Serum creatinine <1.5 mg/dL. Total bilirubin =1.5 x upper limit of normal (ULN) (isolated bilirubin >1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%). Aspartate transaminase (AST) = 3.0 x ULN, except for patients with liver metastasis, who may only be included if AST =5.0 x ULN. Alanine transaminase (ALT) = 3.0 x ULN, except for patients with liver metastasis or tumor infiltration, who may only be included if ALT =5.0 x ULN. Prothrombin time (PT)/International normalized ratio (INR) and Partial thromboplastin time (PTT) =1.5xULN. Note: patients receiving therapeutic anticoagulation agents prior screening are permitted. Albumin 2.5 g/dL.
• Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

Exclusion Criteria:

• History or current diagnosis of cardiac disease indicating significant risk of safety for patients participating in the study such as uncontrolled or significant cardiac disease
• Has had any major surgery, extensive radiotherapy, or anti-cancer therapy (e.g., chemotherapy with delayed toxicity, biologic therapy, or immunotherapy) within 21 days prior to enrolment and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to enrolment. Prolonged immobilization must have resolved prior to enrolment.
• Has a known or suspected carcinoma that is excluded as administration of Oral Contraceptive would be contraindicated.
• Has a history of another malignancy.
• Has a history of interstitial lung disease or pneumonitis.
• Has a history of RVO.
• Has a history of any of conditions that would contraindicate administration of an OC
• Has symptomatic or untreated leptomeningeal, brain metastases, or spinal cord compression. Other protocol-defined Inclusion/Exclusion criteria may apply.

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumors

Intervention

Drug:
• Trametinib
Each tablet is 2mg trametinib to be taken orally once daily.
• Trametinib
Each tablet is 0.5mg trametinib to be taken orally once daily. 0.5mg tablets may be used if a dose reduction is required.
• Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)
Combined oral contraceptive to be taken orally once daily.

Locations

Country	Name	City	State
Belgium	Novartis Investigative Site	Edegem
Belgium	Novartis Investigative Site	Namur
Netherlands	Novartis Investigative Site	Maastricht
Spain	Novartis Investigative Site	Malaga
United Kingdom	Novartis Investigative Site	London
United States	Karmanos Cancer Institute Karmanos Cancer Institute	Detroit	Michigan
United States	University of Oklahoma	Oklahoma City	Oklahoma

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Belgium,  Netherlands,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics parameter: AUCtau of NE and EE alone and in combination with trametinib	To evaluate the effect of multiple doses of trametinib (2 mg once daily) on the steady state pharmacokinetics of combination OC (NE and EE) in female patients with solid tumors.	Day 5 and 6 and 21 and 22
Primary	Pharmacokinetics parameter: AUClast of NE and EE alone and in combination with trametinib	To evaluate the effect of multiple doses of trametinib (2 mg once daily) on the steady state pharmacokinetics of combination OC (NE and EE) in female patients with solid tumors.	Day 5 and 6 and 21 and 22
Primary	Pharmacokinetics parameter: Cmax of NE and EE alone and in combination with trametinib	To evaluate the effect of multiple doses of trametinib (2 mg once daily) on the steady state pharmacokinetics of combination OC (NE and EE) in female patients with solid tumors.	Day 5 and 6 and 21 and 22
Primary	Pharmacokinetics parameter: Tmax of NE and EE alone and incombination with trametinib	To evaluate the effect of multiple doses of trametinib (2 mg once daily) on the steady state pharmacokinetics of combination OC (NE and EE) in female patients with solid tumors.	Days 5 and 6 and 21 and 22
Secondary	Pharmacokinetics parameter: AUClast of M5	Characterize PK of metabolite M5	Day 21 and 22
Secondary	Pharmacokinetics parameter: AUCtau of M5	Characterize PK of metabolite M5	Day 21 and 22
Secondary	Pharmacokinetics parameter: Cmax of M5	Characterize PK of metabolite M5	Day 21 and 22
Secondary	Pharmacokinetics parameter: Tmax of M5	Characterize PK of metabolite M5	Day 21 and 22

External Links

•   A Plain Language Trial Summary is available on novartisclinicaltrials.com
•   Results for CTMT212X2102 can be found on the Novartis Clinical Trial Results Website